IDEAYA Biosciences, Inc. (IDYA)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
40.11 USD
-1.66
(-3.974%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 40.11 |
Hot Take ↕ | Aug. 22, 2026, 3:32 a.m. EDT
The narrative here is a classic biotech tension between a recovering stock price and deteriorating fundamentals. While the share price has rallied nearly 300% over the last six years, the most recent annual performance was a sharp decline, and the company is burning cash with negative gross and operating margins. The balance sheet looks healthy on paper due to low debt, but the free cash flow is negative, meaning the current cash pile will eventually need replenishment via dilution or capital markets. Analysts are optimistic, citing potential catalysts like trial readouts, which explains the heavy options activity focused on volatility. However, without consistent profitability or a proven track record of commercial success, this remains a speculative play on a single data point rather than a solid investment. The recent public offering adds supply pressure, capping near-term upside until the next major clinical milestone is confirmed. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.158345 |
| AutoETS | 0.162978 |
| AutoARIMA | 0.162980 |
| MSTL | 0.166052 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.018 |
| Excess Kurtosis | 0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.444 |
| Revenue per Share | 2.617 |
| Market Cap | 3,870,193,408 |
| Forward P/E | -9.76 |
| Beta | -0.09 |
| Profit Margins | -74.75% |
| Website | https://www.ideayabio.com |
As of Aug. 22, 2026, 3:32 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional move. Call Open Interest is heavily concentrated in-the-money at strikes of $30 and $35, suggesting a floor or a belief in a rebound to current levels, while Put Open Interest is similarly dense at $35 and lower strikes ($25-$30). This 'straddle-like' distribution indicates traders expect a binary event or high volatility (e.g., trial readouts or regulatory news) rather than a steady grind higher. The elevated implied volatility on near-term puts compared to calls further highlights fear of downside gaps despite the recent price recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.6393249 |
| Address1 | 5,000 Shoreline Court |
| Address2 | Suite 300 |
| All Time High | 47.735 |
| All Time Low | 2.95 |
| Ask | 40.34 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 798,700 |
| Average Daily Volume3 Month | 1,095,327 |
| Average Volume | 1,095,327 |
| Average Volume10Days | 798,700 |
| Beta | -0.091 |
| Bid | 29.16 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 12.44 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 40.11 |
| Current Ratio | 10.451 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 41.635 |
| Day Low | 40.04 |
| Debt To Equity | 2.444 |
| Display Name | IDEAYA Biosciences |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -214,195,008 |
| Ebitda Margins | -0.91487 |
| Enterprise To Ebitda | -14.335 |
| Enterprise To Revenue | 13.115 |
| Enterprise Value | 3,070,545,152 |
| Eps Current Year | -4.61122 |
| Eps Forward | -4.10814 |
| Eps Trailing Twelve Months | -1.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 36.8596 |
| Fifty Day Average Change | 3.2504005 |
| Fifty Day Average Change Percent | 0.088183284 |
| Fifty Two Week Change Percent | 63.93249 |
| Fifty Two Week High | 42.68 |
| Fifty Two Week High Change | -2.5699997 |
| Fifty Two Week High Change Percent | -0.06021555 |
| Fifty Two Week Low | 23.23 |
| Fifty Two Week Low Change | 16.880001 |
| Fifty Two Week Low Change Percent | 0.72664666 |
| Fifty Two Week Range | 23.23 - 42.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,558,618,200,000 |
| Float Shares | 90,633,537 |
| Forward Eps | -4.10814 |
| Forward P E | -9.763543 |
| Free Cashflow | -70,847,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Fullday Change | -1.66 |
| Fullday Change Percent | -3.97414 |
| Fullday Price | 40.11 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -0.36405998 |
| Gross Profits | -85,237,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02192 |
| Held Percent Institutions | 1.08213 |
| Implied Shares Outstanding | 96,489,484 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. |
| Long Name | IDEAYA Biosciences, Inc. |
| Market | us_market |
| Market Cap | 3,870,193,408 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_329719147 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -175,020,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,030,365,746 |
| Number Of Analyst Opinions | 13 |
| Open | 41.14 |
| Operating Cashflow | -111,663,000 |
| Operating Margins | -13.80727 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 443 6209 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 40.11 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 41.77 |
| Price Eps Current Year | -8.698349 |
| Price Hint | 2 |
| Price To Book | 3.2242768 |
| Price To Sales Trailing12 Months | 16.530315 |
| Profit Margins | -0.74754 |
| Quick Ratio | 10.213 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -1.66 |
| Regular Market Change Percent | -3.97414 |
| Regular Market Day High | 41.635 |
| Regular Market Day Low | 40.04 |
| Regular Market Day Range | 40.04 - 41.635 |
| Regular Market Open | 41.14 |
| Regular Market Previous Close | 41.77 |
| Regular Market Price | 40.11 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 714,064 |
| Return On Assets | -0.11535 |
| Return On Equity | -0.16216 |
| Revenue Per Share | 2.617 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 96,489,484 |
| Shares Percent Shares Out | 0.1078 |
| Shares Short | 10,398,078 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 9,573,580 |
| Short Name | IDEAYA Biosciences, Inc. |
| Short Percent Of Float | 0.1252 |
| Short Ratio | 14.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | IDYA |
| Target High Price | 65.0 |
| Target Low Price | 31.0 |
| Target Mean Price | 52.15385 |
| Target Median Price | 51.0 |
| Total Cash | 828,955,008 |
| Total Cash Per Share | 8.591 |
| Total Debt | 29,307,000 |
| Total Revenue | 234,127,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.4932 |
| Two Hundred Day Average Change | 6.616802 |
| Two Hundred Day Average Change Percent | 0.1975566 |
| Type Disp | Equity |
| Volume | 714,064 |
| Website | https://www.ideayabio.com |
| Zip | 94,080 |